Tristel (TSTL)

Sector:

Health Care

Index:

FTSE AIM 100

400.00p
   
  • Change Today:
      5.00p
  • 52 Week High: 500.00
  • 52 Week Low: 270.00
  • Currency: UK Pounds
  • Shares Issued: 47.71m
  • Volume: 61,965
  • Market Cap: £190.85m
  • RiskGrade: 180
  • Beta: 0.02

Tristel OPH gets US FDA clearance

By Josh White

Date: Monday 12 May 2025

LONDON (ShareCast) - (Sharecast News) - Tristel announced on Monday that it has received FDA clearance to begin immediate sales of its ophthalmic disinfectant foam, Tristel OPH, in the United States.
The AIM-traded firm said the high-level disinfectant was approved for use on a range of reusable ophthalmic instruments, including tonometers, retinal imaging probes, and biometry devices that come into contact with the cornea.

It said the clearance was a significant opportunity in a market with around 16 million ophthalmic procedures annually across North America.

Tristel said its Tristel OPH product offered a faster and more practical alternative to the only previously FDA-cleared method, which involves chemical soaking in open trays with long contact times and occupational health concerns.

The new product, which has a two-minute contact time and was suitable for point-of-care use, was expected to replace both inefficient soak systems and low-level alternatives such as alcohol wipes.

Tristel said it had established US manufacturing through partner Parker Laboratories, adding that several leading eye institutes were preparing to adopt the product.

"We are delighted to receive FDA clearance for our second high level disinfectant product in the US," said chief executive officer Matt Sassone.

"Tristel OPH directly addresses a long-standing unmet need in ophthalmic device reprocessing-offering a fast, safe and practical alternative to the outdated and often hazardous methods still in use.

"Tristel OPH is the first FDA-cleared HLD specifically validated for use on ophthalmic devices meeting user requirements for efficacy, device compatibility and in-use safety."

Sassone said the company's commercial strategy built on the valuable learnings from launching Tristel ULT in the US.

"With an experienced local team and endorsement from ophthalmic device manufacturers we are well prepared to support early adopters and drive sustained growth in this important market.

"We are very excited to bring this new product to market in the US and perfectly timed to be showcased at the APIC - Association for Professionals in Infection Control and Epidemiology - conference in Phoenix, Arizona mid-June, the largest annual event in the US for reaching critical infection preventionist community and decision makers."

At 1122 BST, shares in Tristel were up 1.52% at 401p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Tristel Market Data

Currency UK Pounds
Share Price 400.00p
Change Today 5.00p
% Change 1.27 %
52 Week High 500.00
52 Week Low 270.00
Volume 61,965
Shares Issued 47.71m
Market Cap £190.85m
Beta 0.02
RiskGrade 180

Tristel Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
94.71% below the market average94.71% below the market average94.71% below the market average94.71% below the market average94.71% below the market average
93.94% below the sector average93.94% below the sector average93.94% below the sector average93.94% below the sector average93.94% below the sector average
Price Trend
6.82% above the market average6.82% above the market average6.82% above the market average6.82% above the market average6.82% above the market average
31.43% above the sector average31.43% above the sector average31.43% above the sector average31.43% above the sector average31.43% above the sector average
Income
13.42% above the market average13.42% above the market average13.42% above the market average13.42% above the market average13.42% above the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average
Growth
85.39% above the market average85.39% above the market average85.39% above the market average85.39% above the market average85.39% above the market average
94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 2
Sell 0
Strong Sell 0
Total 3
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Tristel Dividends

  Latest Previous
  Interim Final
Ex-Div 20-Mar-25 28-Nov-24
Paid 11-Apr-25 20-Dec-24
Amount 5.68p 8.28p

Trades for 21-Jul-2025

Time Volume / Share Price
16:34 1,377 @ 405.00p
16:25 2,500 @ 400.00p
16:08 792 @ 408.51p
16:05 624 @ 400.00p
15:52 1,377 @ 400.00p

Tristel Key Personnel

CEO Matthew (Matt) Giovanni Sassone

Top of Page